Solventum (NYSE:SOLV) announced today that it completed its previously announced acquisition of Acera Surgical.

In December 2025, Solventum announced updated consensus recommendations from an international panel on the clinical use of closed incision negative pressure therapy (ciNPT) with its proprietary ...

Solventum (SOLV) has quietly outperformed the broader market this year, with the stock up about 22% year to date, even after a recent pullback over the past week. See our latest analysis for Solventum ...

Solventum Corporation ( ($SOLV) ) has provided an update. On December 16, 2025, Solventum Corporation reflected on a transformative year, ...

Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The ...

Pzena Investment Management recently released its third-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. Driven by optimism about AI and a ...

New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing. Merck is cutting costs and boosting sales of one of its key blockbuster drugs. After ...

We came across a bullish thesis on Solventum Corporation on Value investing subreddit by raytoei. In this article, we will summarize the bulls’ thesis on SOLV. Solventum Corporation's share was ...

3M Company has restored investor confidence, with shares rising 90% from October 2023 lows amid consistent profitability and moderate growth. MMM has exceeded sales and EPS forecasts for nine ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...